Employees: 7,906
Size Hygeia Healthcare (6078.HK) is a Hong Kong Health Care company (Pharmaceuticals: Major) with a market value of $811M, the 632nd largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$10.66 on 18 Nov 2026.
Performance Over six months the shares fell 2.6%, against -7.7% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — 8th highest of 19 in its peer set.
Growth Revenue grew 1.6% over the last twelve months (peer median +2.8%); the operating margin is 14.2% (peer median 5.0%).
Valuation It trades at 10.4× forward earnings against a peer median of 22.0× (3rd cheapest of 9).
Price implies For today's price to make sense, revenue must grow about 5% a year for seven years (Req g). Recent delivered growth is +23%, so the hurdle is -18 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 3.6 points below its cost of capital (9.0% WACC).
Next results Next results expected around 31 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | HK$4.45B | HK$4.35B | HK$4.82B | HK$4.50B | HK$3.72B |
| Revenue growth | — | -10% | +7% | +21% | — |
| Gross profit | HK$1.15B | HK$1.11B | HK$1.34B | HK$1.34B | HK$1.14B |
| EBITDA | HK$969M | HK$930M | HK$1.23B | HK$1.14B | HK$999M |
| Net income | HK$203M | HK$178M | HK$649M | HK$755M | HK$554M |
| Free cash flow | HK$540M | HK$424M | HK$12.2M | -HK$246M | HK$44.0M |
| Capital expenditure | HK$455M | HK$524M | HK$667M | HK$1.04B | HK$706M |
| Total debt | n/a | HK$2.72B | HK$2.97B | HK$3.00B | HK$1.45B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 6078.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +10.9% | -6.5% | 4th highest of 19 |
| 6-month return | -2.6% | -7.7% | 8th highest of 19 |
| Distance from 52-week high | -26.7% | -34.8% | 5th highest of 19 |
| Revenue growth (TTM) | +1.6% | +2.8% | 8th lowest of 19 |
| Operating margin | 14.2% | 5.0% | 8th highest of 19 |
| Forward P/E | 10.4× | 22.0× | 3rd cheapest of 9 |
| Growth the price implies (Req g, 7 yrs) | 4.6% | 6.6% | 5th least demanding of 10 |
| Growth delivered (Del g) | +22.5% | +10.1% | 2nd highest of 10 |
| Hurdle (Req g minus delivered) | -18.0 pp | -5.1 pp | 3rd least demanding of 10 |
| ROIC minus cost of capital | -3.6 pp | -1.9 pp | 7th lowest of 18 |
| EV / EBITDA | 8.4× | 10.0× | 3rd cheapest of 7 |
| Net debt / EBITDA | 1.8× | -0.5× | 2nd most indebted of 8 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Hygeia Healthcare 6078.HK | Hong Kong | $811M | -3% | +2% | 14% | 10.4× | 4.6% | +22.5% |
| Collegium Pharmaceutical COLL | United States | $806M | -24% | +8% | 15% | 3.7× | -2.6% | +20.3% |
| Suven Life Sciences SUVEN.NS | India | $803M | -1% | +55% | -4,452% | n/a | n/a | n/a |
| Bide Pharmatech 688073.SS | China | $801M | +10% | +10% | 19% | 24.3× | 13.9% | +27.7% |
| Rigel Pharmaceuticals RIGL | United States | $801M | +48% | +2% | 26% | 10.8× | 1.5% | +22.1% |
| Wanbangde Pharmaceutical 002082.SZ | China | $823M | -52% | -38% | -10% | n/a | 27.7% | -39.5% |
| Zhejiang Ausun Pharmaceutical 603229.SS | China | $824M | -34% | +1% | 0% | n/a | n/a | n/a |
| Dezhan Healthcare 000813.SZ | China | $825M | -33% | -10% | -121% | n/a | n/a | n/a |
| Sanofi India SANOFI.NS | India | $797M | 0% | -6% | 26% | 19.6× | 16.3% | -8.7% |
| Oric Pharmaceuticals ORIC | United States | $795M | -9% | n/a | n/a | n/a | n/a | n/a |
| Hunan Er-Kang Pharmaceutical 300267.SZ | China | $829M | -40% | -14% | -29% | n/a | n/a | n/a |
| Knight Therapeutics GUD.TO | Canada | $792M | +41% | +36% | 6% | 42.2× | 6.6% | +17.7% |
| Ironwood Pharmaceuticals IRWD | United States | $791M | +22% | +18% | 63% | 3.5× | n/a | n/a |
| Bambusa Therapeutics BBTX | United States | $791M | n/a | n/a | n/a | n/a | n/a | n/a |
| Jinghua Pharmaceutical 002349.SZ | China | $785M | -8% | +2% | 20% | n/a | -2.5% | +2.6% |
| Ardelyx ARDX | United States | $784M | -50% | +18% | -8% | 252.9× | n/a | n/a |
| Zhejiang Int'l 000411.SZ | China | $783M | -21% | +3% | 3% | n/a | n/a | n/a |
| Sichuan Neautus Traditional Chinese 2206.HK | Hong Kong | $779M | n/a | +7% | 8% | n/a | n/a | n/a |
| Bliss GVS Pharma BLISSGVS.NS | India | $777M | +141% | +25% | 18% | n/a | 33.9% | +10.1% |
| Beijing Sun-Novo Pharmaceutical Research 688621.SS | China | $849M | -8% | -1% | -2% | 29.0× | n/a | n/a |
| Guizhou Xinbang Pharmaceutical 002390.SZ | China | $771M | -7% | -13% | 4% | n/a | -3.8% | -0.8% |